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Abstract
Background: Plasmoblastic lymphoma is a rare and aggressive subtype of diffuse large B cell lymphoma, which
occurs usually in the jaw of immunocompromised subjects.
Case presentation: We describe the occurrence of plasmoblastic lymphoma in the mediastinum and chest wall
skin of an human immunodeficiency virus-negative 63-year-old Caucasian man who had had polycytemia vera 7
years before. At admission, the patient showed a superior vena cava syndrome, with persistent dyspnoea, cough,
and distension of the jugular veins. Imaging findings showed a 9.7 × 8 × 5.7 cm mediastinal mass. A chest wall
neoformation biopsy and ultrasound-guided fine-needle aspiration biopsy of the mediastinal mass allowed
diagnosis of plasmoblastic lymphoma and establishment of an immediate chemotherapeutic regimen, with rapid
remission of compression symptoms.
Conclusions: Plasmoblastic lymphoma is a very uncommon, difficult to diagnose, and aggressive disease. The
presented case represents the first rare mediastinal plasmoblastic lymphoma in a human immunodeficiency virus-/
human herpesvirus-8-negative patient. Pathologists should be aware that this tumor does appear in sites other than
the oral cavity. Fine-needle aspiration biopsy is a low-cost, repeatable, easy-to-perform technique, with a high
diagnostic accuracy and with very low complication and mortality rates. Fine-needle aspiration biopsy could
represent the right alternative to surgery in those patients affected by plasmoblastic lymphoma, being rapid and
minimally invasive. It allowed establishment of prompt medical treatment with subsequent considerable reduction
of the neoplastic tissue and resolution of the mediastinal syndrome.
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Background
By World Health Organization (WHO) classification,
plasmoblastic lymphoma (PBL) is considered to be a new
subtype of diffuse large B cell lymphoma (DLBCL) with
distinct blastic morphology, antigenic phenotyping data
indicating plasmacytic differentiation (CD20−, CD45−,
CD79a+, and VS38c+), and clinical presentation favoring
extramedullary sites, particularly the oral cavity and the
mucosa of the jaw [1]. PBL is associated with human
immunodeficiency virus (HIV) and Epstein–Barr virus
(EBV) co-infection; its incidence has increased since the
introduction of the highly active anti-retroviral therapy
(HAART) [2]. Based on morphology alone, the differential
diagnosis would include lymphoblastic lymphoma,
anaplastic plasmacytoma, plasmablastic variant of BCL
and human herpesvirus-8 (HHV8)-associated PBL.
Although most of the tumors show plasmablastic morph-
ology, express plasma cell antigens, are EBV-positive and
have a high proliferative index, they still remain a hetero-
geneous group with varying clinical presentation and
hence differing treatment approaches. The clinical course
of PBL is characteristically aggressive. It is generally asso-
ciated with early dissemination and poor response to ther-
apy and has a reported median overall survival time of 15
months [3]. Currently, treatment responses are usually
partial and temporary; however, prolonged and durable re-
sponses to chemotherapy have been reported [4–6]. In
one small series, early recognition of this pathological
entity, more aggressive management and better HIV
disease control led to improved outcomes with a me-
dian follow-up on 22 months and the median survival
not yet reached at the time of reporting [7]. This is
the first reported case of mediastinal PBL. Interest-
ingly, the patient affected was HIV-/HHV8-negative.
In this particular case, PBL had a metachronous le-
sion of the chest wall. A prompt detection and mini-
invasive approach allowed our patient to recover
within a few cycles of chemotherapy.
Case presentation
A 63-year-old Caucasian man was referred to our hospital
with a 3-month history of dyspnoea, hacking cough, and
distended jugular veins.
Seven years before, a complete blood cell count had re-
vealed polyglobulia. The subsequent bone marrow biopsy
showed a cellularity of 70%, with trilinear expansion; the
myelo-erythroid ratio was 5:1, with preserved maturation.
The proliferative megakaryocytic series were slightly poly-
morphic, with little tendency to cluster aggregation. The
histology was highly suspicious for an initial phase of poly-
cythemia vera (Vasquez disease). After diagnosis, our
patient was placed on oral administration of 1,4-bis (3-bro-
mopropionyl) piperazine 25 mg and hydroxyurea 500 mg.
Three years later, JAK2 V617F mutation was found. Our
patient did not refer for any further relevant medical issue.
On physical examination, our patient showed facial rash,
periorbital and facial edema, distension of the jugular
veins, bilateral disappearance of his supraclavicular fossae,
mild ptosis especially on the right side, and a chest wall
formation, just upon the projection of the sixth right rib,
of hard consistency (Fig. 1). A neurological examination
was negative. Our patient showed signs neither of laryn-
geal and phrenic nerve involvement (dysphonia, hiccough)
nor of abnormal sympathetic response (Bernard-Horner
syndrome).
Fig. 1 Facial rash, periorbital and facial edema, bilateral
disappearance of the supraclavicular fossae
Fig. 2 Chest X-ray; antero-posterior view. Upper mediastinal widening
due to a mediastinal mass (10 cm × 6 cm), more evident on the right
side, with polycyclic margins; the angles with the mediastinal contour
are obtuse. The hilar vessels cannot be seen through the mass
(“hilum overlay sign” absent). The paravertebral line can be
recognized. These two findings confirm that this mass is located in
the superior-anterior-middle mediastinum. Trachea is deviated
laterally to the right side by the mediastinal mass. At the right
inferior chest wall subcutaneous tissue mass can be detected
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Blood test results showed relative (17.5%) and absolute
(1.57*103/μL) lymphocytosis; his lactate dehydrogenase
(LDH) was 423 U/L; C-reactive protein (CRP) 1.8 mg/
dL; fibrinogen 414 mg/dl; immunoglobulin A (IgA) 549
mg/dL; erythrocyte sedimentation rate (ESR) was 27
mm; β2-microglobulin was 2.6 mg/dL. Our patient was
negative for hepatitis C (HCV), HHV8 and HIV, but
positive for hepatitis B (HBV) (HBc IgG: 627 mIU/mL)
and EBV.
A chest X-ray detected a bilateral flaring, especially in
the upper right side; the trachea was deviated on the
right (Fig. 2). A total body computed tomography (CT)
scan, performed a few days after admission, showed a
polylobed solid heteroplasia to the anterior-superior
mediastinum, iso-hypodense after contrast, of 9.7 cm in
its transverse diameter, 8 cm in its cranio-caudal diam-
eter and 5.7 cm in its antero-posterior diameter. The
heteroplasia compressed the right jugular vein and the
superior vena cava. The visible chest wall formation
showed the same radiological characteristics as the
mediastinal one (Fig. 3). No lesion was found in our
patient’s abdomen or skull.
One month after a total body CT scan, another chest
CT scan was performed: in this case, the mass showed
increased dimensions, being 12 cm in transverse diam-
eter, 14 cm in cranio-caudal diameter and 7.5 cm in
antero-posterior diameter (Fig. 4).
One month later, a neck ultrasound (US) scan showed a
thrombosis of the right internal jugular vein with signs of
recanalization, despite previous anticoagulation therapy.
The left internal jugular vein was patent (Fig. 5).
A diagnostic mediastinal ultrasound (US)-guided fine-
needle aspiration biopsy (FNAB) was performed with
local anesthesia, using a low-frequency probe (3.5 MHz),
(Fig. 6a). The mediastinal mass was showed as a hypo-/
anechoic formation at the depth of 35 mm, with a 46.7
mm antero-posterior diameter and 82.1 mm transverse
diameter (Fig. 6b). Contemporaneously, the chest wall
neoformation was resected, always under local anesthesia
with lidocaine 20% and naropine 1%. No complication
occurred during and after surgery. Both samples were sent
to pathologists.
Histological examination of the mediastinal FNAB and
the chest wall biopsy gave the same results: resected tissue
widely occupied by a monomorphic lymphoid proliferation
(Fig. 7a) composed of large-size cells with evident nucleoli,
typical of a high-grade non-Hodgkin’s B cell lymphoma [8,
9]. Morphological and immunophenotypic findings (Fig. 7b,
c, d) (PanCK, CK20, chromogranin, NSE were also nega-
tive) were compatible with the diagnosis of PBL.
Our patient was pharmacologically treated with
EPOCH, a combined therapy of intravenous etoposide (50
mg/m2/day), vincristine (0.4 mg/m2/day), and doxorubicin
(10 mg/m2/day) for 96 hours with bolus doses of cyclo-
phosphamide (750 mg/m2/day) and oral prednisone (60
mg/m2/bid) [10]. Treatment response was good, with a
prompt regression of symptoms after the first cycle. Our
patient received five cycles of combination chemotherapy
with good response. After 10 years, our patient is still alive
and healthy with no clinical or radiological evidence of
recurrent or residual disease.
Discussion
PBL is characterized by its predilection of involving the
oral cavity of HIV-positive individuals as originally
described [1]. Following the first report, a number of
cases have been reported in extraoral sites, in HIV-
positive cases. The most commonly affected sites are the
gastrointestinal tract, lymph nodes, and skin [3, 11–14].
A similar pattern is seen in patients with HIV-negative
PBL, with the oral cavity and gastrointestinal tract being
the most commonly involved sites [15]. The frequency
of oral involvement is higher in HIV-positive (58%) than
in HIV-negative patients (16%) [16]. Other less
Fig. 3 Chest contrast-enhanced computed tomography scan. a Mediastinal window and b lung window: large mediastinal mass (axial: 9.7 × 5.7 cm;
longitudinal: 8 cm) formed by multiple confluent lymph nodes with a heterogeneous contrast enhancement that involves the anterior-middle
mediastinum. The mass is compressing the jugular vein and the superior cava vein
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common extraoral sites include the central nervous sys-
tem [17, 18], paranasal sinuses [18, 19], lungs [19–21],
liver [21], and testes [12, 22]. Bone marrow involve-
ment has been reported at 30% in both HIV-positive
and HIV-negative patients [16]. PBL has also been
documented to arise from longstanding sacrococcygeal
cysts in HIV-positive persons [4]. In a literature review
of 228 patients with PBL, 157 patients (69%) were HIV-
positive and 71 (31%) were HIV-negative [16]; among
HIV-negative patients, 33% of the patients had some
Fig. 4 Chest computed tomography scan. a Mediastinal window and b lung window: mediastinal mass 1 month later (axial 12 × 7.5 cm;
longitudinal 14 cm). The size of the heteroplasia increased about 10%
Fig. 5 Jugular vein echography. a Right internal jugular vein
thrombosis, in transverse and longitudinal sections. A heterogeneous
echogenic material fills and distends the right internal jugular vein; b
comparison of the right and left internal jugular veins. Ultrasonography
shows different diameter between the two vessels
Fig. 6 Intercostal chest echography (second right intercostal space).
a Ultasound image shows a thin-walled hypo-anechoic formation in
the anterior mediastinum (46.7 mm in anteroposterior and 82.1 mm
in laterolateral diameter); b fine-needle aspiration biopsy
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form of immunosuppression, most often solid organ
transplantation or steroid therapy [23]. The remainder
of the HIV-negative patients were apparently immuno-
competent. In a recent case series from Korea, none of
the patients reported showed evidence of immunosup-
pression [24]. In this rare case, our patient had no
evidence of HIV or HHV-8 infections, and he was
apparently healthy. We can postulate that PBL devel-
oped years before, probably when he had his cycles of
chemotherapy for his polycythemia. The size of the
mediastinal mass (9.7 × 8 × 5.7 cm) could confirm this
hypothesis. In such a case, an accurate histological
evaluation of the endothoracic mass is crucial to estab-
lish the optimal medical treatment, in particular when a
morbid surgery is the alternative [20]. Excisional biopsy
should be the gold standard; however, when the site of the
disease is difficult to access, as in this case, core needle
biopsy and FNAB may be performed in conjunction with
appropriate ancillary techniques for the diagnosis and dif-
ferential diagnosis. In fact, the histopathological features
are frequently ambiguous, thus rendering the correct diag-
nosis quite difficult. This neoplasm may be confused with
the plasmablastic type of plasma cell myeloma; however,
the absence of serum monoclonal protein and lack of sig-
nificant bone marrow involvement may argue against this
diagnosis [1]. In addition, PBL is almost entirely composed
of blasts with numerous mitotic figures. These features
are not typical for plasma cell myeloma. The plasma cell
markers VS38c, CD38, multiple myeloma oncogene-1
(MUM1), and CD138 (syndecan-1) seem to be almost uni-
versally expressed [3, 9, 25]. PBL is characterized by a high
proliferation index reflected by Ki67 expression, usually >
80%. Immunophenotypically, the neoplastic cells lacked B
cell-associated antigens (CD20, CD45RA, and CD79a). T
cell-associated antigens (CD3 and CD45RO) as well as
leukocyte common antigen (CD45) were also absent. The
neoplastic cells expressed plasma cell-associated antigens
CD138 and VS38c. Transthoracic FNAB allowed making
the right diagnosis thus saving the patient uncomfortable,
more invasive, procedures, like in other similar cases [20].
Both biopsies, mediastinal and cutaneous, were performed
under local anesthesia, and our patient was allowed to
start his chemotherapy promptly. An aggressive medical
therapy resolved, just after the first cycle and without inva-
sive surgery, our patient’s superior vena cava syndrome
(cutaneous rash, right palpebral ptosis, dyspnoea, cough)
[26].
PBL is a therapeutic challenge with a clinical course
characterized by a high rate of relapse and death. The
prognosis is generally poor, with most patients dying
within 2 years from initial presentation, and long-term
survivors are very few. Patients carrying the MYC/IgH
gene rearrangement have been shown to have a very
poor median overall survivor of only 3 months.
A standard therapy has not yet been established. Treat-
ment usually consists of chemotherapy with or without
consolidation radiation and hematopoietic stem cell trans-
plantation [27]. Various chemotherapy regimens including
cyclophosphamide, doxorubicin, vincristine, and prednis-
one (CHOP), R-CHOP, and cyclophosphamide, vincristine,
doxorubicin, high-dose methotrexate/ifosfamide, etopo-
side, and high-dose cytarabine (CODOX-M/IVAC) are
Fig. 7 Fine-needle aspiration biopsy histology. a Monomorphic lymphoid proliferation composed of large-size cells with evident nucleulus, typical
of a high-grade malignant non-Hodgkin’s B cell lymphoma; b immunophenotypic LCA+, CD20 ; c immunophenotypic CD79a+, MUM1+, CD38+,
CD138+; d immunophenotypic κ+, λ , CD56 , CD30 , ALK1 , CD3 , CD5 , CD10 , bcl-2 , bcl-6 , TdT , LMP1 , Ki-67: 85%
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also possible options [10, 28]. Patients with PBL who were
not treated with chemotherapy invariably died with a
median survival of 3 months [16]. Due to disappointing
response and survival rates, the National Comprehensive
Cancer Network (NCCN) guidelines recommend against
CHOP in favor of more intensive regimens, such as
intravenous EPOCH, cyclophosphamide, vincristine,
doxorubicin, and dexamethasone (hyper-CVAD), or
CODOX-M/IVAC [10]. One of the newest therapeutic
options for PBL is bortezomib, which is a proteasome
inhibitor and a cornerstone in myeloma and relapsed
or refractory mantle cell lymphoma therapy [29].
Some studies have reported that the proteasome
inhibitor bortezomib alone or in combination with
chemotherapy may have an antitumor effect in PBL
or overcoming the typical chemoresistance of this
disease. For the same reason, the use of lenalidomide
has been reported in PBL [30]. In the presented case,
the EPOCH scheme brought the best outcome, with a
rapid response, a prompt resolution of compression
symptoms and a final complete recovery.
Conclusions
PBL is a very uncommon, difficult to diagnose, and
aggressive disease. The presented case represents the first
rare mediastinal PBL in a HIV-/HHV8-negative patient.
Pathologists should be aware that this tumor does appear
in sites other than the oral cavity. Because of its cohesive
histologic appearance, this tumor can be misinterpreted as
being a nonlymphoid tumor, particularly with the
leukocyte common antigen negativity that is typical of this
neoplasm. In a small biopsy specimen, the diagnosis can
be even more problematic and challenging for the
pathologist.
A timely detection and a prompt treatment is mandatory
to avoid life-threatening consequences. The FNAB could
be a low-cost, repeatable, easy-to-perform technique, with
a high diagnostic accuracy and with very low complication
and mortality rates. FNAB could represent the right alter-
native to surgery in those patient affected from PBL, being
rapid and mininvasive. It allowed establishment of a
prompt medical treatment with a subsequent considerable
reduction of the neoplastic tissue and the resolution of the
mediastinal syndrome.
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